CINCINNATI--(BUSINESS WIRE)--LIB Therapeutics Inc. (LIB), a late-stage biopharmaceutical company developing subcutaneous and oral PCSK9 inhibitor therapies for patients at very high and high-risk of ...
CINCINNATI--(BUSINESS WIRE)--LIB Therapeutics Inc. (LIB), a privately-held, late-stage biopharmaceutical company developing Lerodalcibep, a novel, third-generation PCSK9 inhibitor for patients at very ...
Once-monthly, third-generation PCSK9 inhibitor now available with direct-to-patient cash-pay option at $199 per month, a substantial discount to other PCSK9 inhibitors direct-to-patient cash prices1,2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results